本帖最后由 老马 于 2012-1-13 21:20 编辑
& F# d5 n! n. [6 ]9 [6 Q* g1 o4 |* R M0 V l3 ?
爱必妥和阿瓦斯丁的比较' |9 u+ K' }0 o' z
, i; M0 n% n5 i& v3 V/ ] L) {
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/2 t! |3 k4 j& B1 s6 f
) e! f8 e6 ]5 T" i" u
0 _ Y' |" c/ j- ghttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial// [/ U2 l* k. {% |& q6 l" P
==================================================
/ v' F5 `7 R! S. C) y1 ~( {0 OOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL); a1 T8 w5 u$ R
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
9 N- S2 n! X: [7 U# wResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
; z# ^9 a2 Q7 Y0 s7 j
|